MedTrace Logo

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

NCT07167329 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-11

No results posted yet for this study

Summary

The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.

Conditions

  • Von Hippel Lindau
  • Von Hippel Lindau Disease
  • Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
  • Hemangioblastoma (HB) of the Central Nervous System (CNS)
  • PNET
  • Retinal Angiomatous Proliferation
  • Pheochromocytoma/Paraganglioma
  • Endolymphatic Sac Tumor

Interventions

DRUG

Belzutifan

Patients with Von Hippel-Lindau Syndrome presenting with lesions or neoplasms requiring treatment with oral Belzutifan.

Sponsors & Collaborators

  • AC Camargo Cancer Center

    collaborator OTHER

  • José Claudio Casali da Rocha

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2026-02-01
Completion
2030-01-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07167329 on ClinicalTrials.gov